A Study on Safety and Efficacy of Two Doses of Topiramate as Monotherapy in the Treatment of Newly Diagnosed or Recurrent Epilepsy

Johnson & Johnson (J&J)

Status and phase

Completed

Phase 3

Conditions

Epilepsy, Generalized

Seizures

Epilepsy

Epilepsy, Tonic-Clonic

Epilepsies, Partial

Treatments

Drug: topiramate

Study type

Interventional

Funder types

Industry

Identifiers

NCT00231556

CR003259

Details and patient eligibility

About

The purpose of this study is to compare the safety and effectiveness of two doses of topiramate as monotherapy in the treatment of pediatric and adult patients with newly diagnosed or recurrent epilepsy.

Full description

Topiramate is approved for treating epilepsy in combination with other epilepsy drugs, but not approved for treating epilepsy as sole treatment or in recently diagnosed epilepsy characterized by partial-onset seizures. This is a randomized, double-blind, parallel-group, multicenter study to compare the safety and effectiveness of two doses of topiramate as monotherapy in pediatric and adult patients with newly diagnosed (within 3 months) or recurrent epilepsy (partial-onset or primary generalized tonic-clonic). The study consists of 4 phases: Baseline (assessment of seizure frequency and other eligibility), Open-Treatment (all patients receive 25 milligrams[mg]/day of topiramate for 7 days), Core Double-Blind Phase (patients are randomized to receive either their assigned dose of topiramate of 50mg/day or 400mg/day, or maximum tolerated dose, and then remain, if possible, on that dose for the duration of the double-blind phase; they continue to receive the medication until they experience the first seizure or until 6 months after the last patient is enrolled), and Long-Term Extension Phase (patients continue to receive the medication at maximum tolerated dose, which may be adjusted according to individual tolerability and effectiveness, until either the patient withdraws or the sponsor terminates the study). The study hypothesis is that topiramate will be effective in the treatment of newly diagnosed or recurrent epilepsy in dose-dependent manner. Topiramate tablets (25 milligrams[mg]) daily by mouth in once-daily regimen during the 7-day Open-Treatment Phase; topiramate twice daily for total of 50mg/day or 400mg/day during the Double-Blind Phase.

Enrollment

750 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

Weigh >=25 kilograms
Diagnosis of epilepsy within 3 months prior to study entry or recurrence of epilepsy while off of anit-epileptic drugs
No more than two documented seizures during the three-month retrospective baseline phase
may have experienced seizures prior to the three-month, retrospective baseline phase
Patients with partial-onset seizures, with or without a secondarily generalized component, and generalized seizures, including tonic-clonic (grand mal), tonic, clonic, juvenile myoclonic epilepsy (impulsive petit mal) and myoclonic epilepsy
Receiving either no other concomitant anti-epileptic drug (AED) or be on one standard AED.

Exclusion criteria

Patients who do not have epilepsy
Patients with absence (petit mal) or atypical absence seizures, epilepsia paritlis continua, cluster pattern or serial seizures
Patients with progressive neurological or degenerative disorder
Patients with significant history of unstable medical diseases
Patients with a drug allergy or hypersensitivity to carbonic anhydrase inhibitors or sulfa drugs
Patients with history of alcohol or drug abuse within past one year
Patients with a history of suicide attempt within past one year.